Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis.

BMC cancer - 12 Nov 2024

Liu Ao, Wang Xiaoming, Wang Lian, Zhuang Han, Xiong Liubo, Gan Xiao, Wang Qian, Tao Guanyu

Abstract excerpt

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and EGFR-TKI combination treatments have become the standard first-line treatments for EGFR-mutated non-small cell lung cancer (NSCLC) patients. However, the best option has yet to be determined. This study compares the efficacy and safety of various first-line EGFR-TKI monotherapies and combination treatments for advanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Progression-Free Survival

Share to Randomized Controlled Trials as Topic

Share to Treatment Outcome

Share to Tyrosine Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 39533233
DOI: 10.1186/s12885-024-13168-8
PMCID: PMC11555867

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis.PMID 39533233Read ↗

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR- mutated NSCLC: a network meta-analysisSemantic proximity Read ↗

Efficacy and safety of first-line treatments for patients with advanced epidermal growth factor receptor mutated non-small cell lung cancer: a network meta- analysisSemantic proximity Read ↗

A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?Semantic proximity Read ↗

Comparation of EGFR-TKI (EGFR tyrosine kinase inhibitors) combination therapy and osimertinib for untreated EGFR-mutated advanced non-small cell lung cancers: A systematic review and network meta-analysis.Semantic proximity Read ↗

Front-line Therapy in Advanced Non-Small Cell Lung Cancer With Sensitive Epidermal Growth Factor Receptor Mutations: A Network Meta-analysis.Semantic proximity Read ↗

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysisSemantic proximity Read ↗

First-line treatment for advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer: a network meta-analysisSemantic proximity Read ↗

Efficacy and Safety of Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation: a Network Meta-AnalysisSemantic proximity Read ↗

Network meta-analyses for EGFR mutation-positive non-small-cell lung cancer: systematic review and overview of methods and shortcomings.Semantic proximity Read ↗

What is the optimal first-line regimen for advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation: a systematic review and network meta-analysis.Semantic proximity Read ↗

Efficacy and safety of anlotinib plus EGFR-TKI for advanced non-small cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Meta-analysis of Targeted Therapies in EGFR-mutated Non-Small Cell Lung Cancer: Efficacy and Safety of Osimertinib, Erlotinib, and Gefitinib as First-line Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.